Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Dirk Kropeit"'
Autor:
Dirk Kropeit, Susanne Bonsmann, Oliver von Richter, David McCormick, Jörg Pausch, Melanie Sumner, Alexander Birkmann, Holger Zimmermann, Helga Rübsamen‐Schaeff
Publikováno v:
Clinical Pharmacology in Drug Development.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c5887c1fe383470f851d2912aa34596
https://doi.org/10.1002/cpdd.1241
https://doi.org/10.1002/cpdd.1241
Autor:
Holger Zimmermann, Katharina Erb-Zohar, Dirk Kropeit, Helga Rübsamen-Schaeff, Jochen G W Theis, Hans-Peter Stobernack, Jürgen Scheuenpflug, David McCormick
Publikováno v:
Clinical Pharmacology in Drug Development. 11:6-15
Letermovir is a human cytomegalovirus (CMV) terminase inhibitor approved in the United States, Canada, Japan, and the European Union for prophylaxis of CMV infection and disease in CMV-seropositive, allogeneic, hematopoietic stem-cell transplant reci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f276ca77abc2db5660ed2a77f8643bef
https://doi.org/10.1002/cpdd.1043
https://doi.org/10.1002/cpdd.1043
Autor:
Alexander Birkmann, Susanne Bonsmann, Dirk Kropeit, Tamara Pfaff, Manickam Rangaraju, Melanie Sumner, Burkhard Timmler, Holger Zimmermann, Helmut Buschmann, Helga Ruebsamen-Schaeff
Publikováno v:
Journal of medicinal chemistry. 65(20)
When the nucleoside analogue acyclovir was introduced in the early 1980s, it presented a game-changing treatment modality for herpes simplex virus infections. Since then, work has been ongoing to improve the weaknesses that have now been identified:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b69be1720a16217550c44fc70babd502
https://pubmed.ncbi.nlm.nih.gov/36202389
https://pubmed.ncbi.nlm.nih.gov/36202389
Publikováno v:
Current drug metabolism. 22(10)
Background: Letermovir is approved for prophylaxis of cytomegalovirus infection and disease in cytomegalovirus-seropositive hematopoietic stem-cell transplant (HSCT) recipients. Objective: HSCT recipients are required to take many drugs concomitantly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bd3c70b783695fabe34973d8d747161
https://pubmed.ncbi.nlm.nih.gov/33622223
https://pubmed.ncbi.nlm.nih.gov/33622223
Autor:
Valentin S. Moiseev, David McCormick, Holger Zimmermann, Dirk Kropeit, Zhanna Kobalava, Katharina Erb-Zohar, Hans-Peter Stobernack, Helga Rübsamen-Schaeff
Publikováno v:
British Journal of Clinical Pharmacology. 83:2678-2686
Aims Human cytomegalovirus constitutes a prevalent and serious threat to immunocompromised individuals and requires new treatments. Letermovir is a novel viral-terminase inhibitor that has demonstrated prophylactic/pre-emptive activity against human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10feb9d01e71ea92d125e6d5f3495f31
https://doi.org/10.1111/bcp.13376
https://doi.org/10.1111/bcp.13376
Autor:
Katharina Erb-Zohar, David McCormick, Helga Rübsamen-Schaeff, Holger Zimmermann, Hans-Peter Stobernack, Dirk Kropeit
Publikováno v:
Clinical pharmacology in drug developmentReferences. 11(1)
Letermovir is a human cytomegalovirus (CMV) terminase inhibitor for the prophylaxis of CMV infection and disease in allogeneic hematopoietic stem-cell transplant recipients. In vitro studies have identified letermovir as a potential cytochrome P450 (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9316c1200ae6f122f1b928345d93edec
https://pubmed.ncbi.nlm.nih.gov/34714967
https://pubmed.ncbi.nlm.nih.gov/34714967
Autor:
Alexandra Bigge, Daniela Paulsen, Christiane Vank, Thomas Berg, Silke Kummer, Ibironke Addy, Holger Zimmermann, Johanna M Eberhard, Dirk Kropeit, Marcus Altfeld, Alen Jambrecina, Manickam Rangaraju, Katja Nedoschinsky, Florian van Bömmel, Hans-Peter Stobernack, Julian Schulze zur Wiesch, Urte Matschl, Adam J. Gehring
Publikováno v:
Journal of Hepatology. 70:e478-e479
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9a30209a77168e86448eb5a38ef8a07
https://doi.org/10.1016/s0618-8278(19)30944-2
https://doi.org/10.1016/s0618-8278(19)30944-2
Autor:
Egj Hulskotte, H-P Stobernack, Dirk Kropeit, Katharina Erb-Zohar, Holger Zimmermann, Helga Rübsamen-Schaeff, J Scheuenpflug, A van Schanke
Publikováno v:
Clinical and Translational Science
Letermovir is a novel antiviral in clinical development for prophylaxis against human cytomegalovirus in immunocompromised transplant recipients. This two‐part, single‐center, randomized, double‐blind, placebo‐controlled trial evaluated the s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::676b9d59c465c31e382e0bc80b40c3c4
https://pubmed.ncbi.nlm.nih.gov/28675594
https://pubmed.ncbi.nlm.nih.gov/28675594
Autor:
Holger Zimmermann, Oliver von Richter, Dirk Kropeit, Hans-Peter Stobernack, Helga Rübsamen-Schaeff
Publikováno v:
Clinical pharmacology in drug development. 7(1)
Letermovir is being developed for human cytomegalovirus infection treatment and prophylaxis. In patients receiving transplants, antivirals are coadministered with cyclosporine A (CsA) or tacrolimus (TAC) immunosuppressants. Therefore, we investigated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab9a6d9271157e25926b13888aacec07
https://pubmed.ncbi.nlm.nih.gov/30840357
https://pubmed.ncbi.nlm.nih.gov/30840357
Autor:
Dirk, Kropeit, Jürgen, Scheuenpflug, Katharina, Erb-Zohar, Atef, Halabi, Hans-Peter, Stobernack, Ellen G J, Hulskotte, Arne, van Schanke, Holger, Zimmermann, Helga, Rübsamen-Schaeff
Publikováno v:
British journal of clinical pharmacology. 83(9)
Human cytomegalovirus remains a significant issue for immunocompromised patients and existing viral polymerase targeting therapies are associated with significant toxicity. Accordingly, the viral terminase complex inhibitor, letermovir, is in develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::422b2a0b9342a4696d33f51036c2b05d
https://pubmed.ncbi.nlm.nih.gov/28345163
https://pubmed.ncbi.nlm.nih.gov/28345163